TN-TYPE-ONE-ENERGY
30.7.2024 14:01:33 CEST | Business Wire | Press release
Type One Energy announced today the final closing of its $82.4 million seed financing round, attracting a broad base of global investors to the Company and its FusionDirect program, which is pursuing a direct path to commercializing fusion energy. FusionDirect is intended to culminate in the launch of Type One Energy’s fusion pilot power-plant project with an owner/operating partner by 2030.
Prominent new shareholders in Type One Energy include Centaurus Capital, GD1 from New Zealand, together with Foxglove and other funds from Australia. This global support highlights the growing international conviction that stellarator fusion technology can play a critical role in completing the transition to a net zero carbon emissions energy system. Fusion energy, unlike traditional nuclear fission, is the power of the stars - fueled from sea water, deployable anywhere, intrinsically safe, and leaving no long-term waste. These unique attributes of fusion energy are what makes the technology increasingly compelling to stakeholders in the future of energy.
The Asia-Pacific (APAC) region features prominently in Type One Energy’s seed financing, with funds from both New Zealand and Australia making first-time investments in fusion energy. The Co-Managing Partner of New Zealand’s GD1 fund, Vignesh Kumar, stated: “The progress Type One Energy has achieved in its FusionDirect program, its access to critical infrastructure such as Oak Ridge National Lab’s supercomputing resources, support from the US DOE Milestone Fusion Development Program, and its focus on advancing the FusionDirect program in the ASEAN region including across New Zealand, made an investment into the team and company a very compelling thesis for us.” Complementing GD1’s decision to become a Type One Energy shareholder, important elements of Australia’s venture capital market joined this financing round. Foxglove’s CEO Gareth Hicks, based in Perth, offered the following comment about Australia’s engagement in Type One Energy: “We are committed to the energy transition, and we want to participate in the value chain of new solutions to key global challenges. Type One Energy’s partner-based approach to fusion commercialization is important to us.”
In addition to bringing new investors into the fusion sector, Type One Energy attracted significant commitments from long-time investors in the industry, including Breakthrough Energy Ventures (BEV) co-founder and founder of Centaurus Capital, John Arnold.
“The successful commercialization of fusion energy will play a critical role in achieving clean, abundant energy,” said Carmichael Roberts, from Breakthrough Energy Ventures. “Stellarator fusion technology now offers the opportunity to directly develop and deploy a fusion pilot power plant without the need to resolve any more fundamental science or engineering challenges and Type One Energy has assembled a great team and strategy to accelerate the deployment of fusion technology globally.”
Type One Energy continues to attract some of the fusion sector’s best technical and business leadership talent. With four locations across North America and ongoing initiatives to further engage global talent, resources and energy transition stakeholders, the company is delivering on its strategy to execute a partner-rich, capital-efficient, decadal path to fusion commercialization.
“By aligning our financing round with rapid, thoughtful expansion of our organizational capabilities, we have been able to demonstrate unique credibility and shareholder value in the private fusion industry,” said Type One Energy Group CEO Christofer Mowry. He added that “we appreciate the confidence of new stakeholders in the success of this essential element of a low carbon future of energy. We have taken the time needed to bring them up the learning curve on this new technology and its path to commercialization.”
About Type One Energy
Type One Energy Group is mission-driven to provide sustainable, affordable fusion power to the world. Established in 2019 and venture-backed in 2023, the company is led by a team of globally recognized fusion scientists with a strong track record of building state-of-the-art stellarator fusion machines, together with veteran business leaders experienced in scaling companies and commercializing energy technologies. Type One Energy applies proven advanced manufacturing methods, modern computational physics and high-field superconducting magnets to develop its optimized stellarator fusion energy system. Our FusionDirect development program pursues the lowest-risk, shortest-schedule path to a fusion power plant over the coming decade, using a partner-intensive and capital-efficient strategy. We are committed to diversity, inclusion, and equitable access to clean energy. For more information, visit www.typeoneenergy.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730842030/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
